HC Wainwright Cuts Earnings Estimates for X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - HC Wainwright lowered their FY2028 EPS estimates for X4 Pharmaceuticals in a note issued to investors on Friday, February 7th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.02 for the year, down from their prior forecast of $0.04. HC Wainwright currently has a "Buy" rating and a $1.50 target price on the stock. The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals' FY2029 earnings at $0.16 EPS.

Separately, Stifel Nicolaus lowered their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, November 14th.

X4 Pharmaceuticals Stock Up 4.6 %

X4 Pharmaceuticals stock traded up $0.02 during midday trading on Monday, hitting $0.50. 1,239,044 shares of the stock were exchanged, compared to its average volume of 5,764,367. X4 Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $1.60. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The firm has a market cap of $85.72 million, a P/E ratio of -5.58 and a beta of 0.12. The company has a 50 day moving average price of $0.60 and a two-hundred day moving average price of $0.59.

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN raised its stake in X4 Pharmaceuticals by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company's stock worth $58,000 after acquiring an additional 26,763 shares during the period. Geode Capital Management LLC boosted its stake in X4 Pharmaceuticals by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 3,497,212 shares of the company's stock valued at $2,566,000 after acquiring an additional 49,700 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of X4 Pharmaceuticals by 501.0% during the fourth quarter. JPMorgan Chase & Co. now owns 459,653 shares of the company's stock valued at $337,000 after purchasing an additional 383,177 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth approximately $44,000. Finally, SG Americas Securities LLC raised its position in shares of X4 Pharmaceuticals by 233.0% during the 4th quarter. SG Americas Securities LLC now owns 183,152 shares of the company's stock worth $134,000 after purchasing an additional 128,148 shares during the period. 72.03% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the transaction, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Adam S. Mostafa sold 74,773 shares of the company's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. In the last three months, insiders sold 202,663 shares of company stock worth $91,198. 1.62% of the stock is currently owned by insiders.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.